摘要
特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是病因不明,组织病理学主要为普通间质性肺炎,局限于肺部的慢性纤维化型间质性肺炎。该病致死率高,对人群健康危害性高。近年来,随着人口老龄化、空气污染的加剧导致其发病率逐年上升,我们对于IPF的认识也在不断提高,研究发现IPF患者常合并其他疾病,包括肺气肿、肺癌、心血管疾病等。存在合并症的IPF患者临床症状更多,患者的生存质量差。其中合并肺动脉高压会降低IPF患者的生存率,本文就IPF合并肺动脉高压进行综述,以期为IPF合并肺动脉高压的诊疗方案与进一步研究提供新思路,以期提高IPF患者的生活质量及改善预后。
Idiopathic pulmonary fibrosis(IPF)is of unknown etiology,and the histopathology is mainly common interstitial pneumonia,which is confined to the lung of chronic fibrotic interstitial pneumonia.The disease has a high fatality rate and is harmful to human health.In recent years,with the aging of the population and the aggravation of air pollution,the incidence of IPF has increased year by year.Our understanding of IPF has also been improved.Studies have found that IPF patients are often complicated with other diseases,including emphysema,lung cancer and cardiovascular diseases.IPF patients with comorbidities had more clinical symptoms and poor quality of life.Among them,the combination of pulmonary hypertension can reduce the survival rate of IPF patients.This article reviews the combination of IPF and pulmonary hypertension in order to provide new ideas for the diagnosis and treatment of IPF and further research to improve the quality of life and prognosis of IPF patients.
作者
王雪立
杨丽青
高凌云
WANG Xue-li;YANG Li-qing;GAO Ling-yun(University of Electronic Science and Technology of China,Chengdu,610054 China;Department of Respiratory and Critical Care Medicine,Sichuan Academy of Mdedical Science&East Ward of Sichuan Provincial People's Hospital,Chengdu 610100,China)
出处
《实用医院临床杂志》
2024年第2期17-21,共5页
Practical Journal of Clinical Medicine
基金
四川省科技厅重点研发项目(编号:23ZDYF1850)
四川省医疗卫生与健康促进会课题(编号:KY2022SJ0116)
成都市科技局重大科技应用示范项目(编号:2022-YF09-00003-SN)。
关键词
特发性肺纤维化
肺动脉高压
合并症
诊治进展
Idiopathic pulmonary fibrosis
Pulmonary hypertension
Complication
Progress in diagnosis and treatment
